Skip to main content
. Author manuscript; available in PMC: 2013 Oct 5.
Published in final edited form as: Vaccine. 2012 Sep 1;30(45):6359–6367. doi: 10.1016/j.vaccine.2012.08.051

Figure 1.

Figure 1

Immune responses at mucosal surfaces after αDEC:LcrV immunization in the presence of poly IC and αCD40 as adjuvants. (A) BALB/c mice were immunized with PBS, F1-V (10 μg) adsorbed in alum, αDEC:LcrV (10 μg), or αDEC:empty (10 μg) in the presence of adjuvants (50 μg of poly IC and 25 μg of αCD40 mAb) either i.n. or s.c. Ten days later, lungs were collected, restimulated with the LcrV reactive peptide LKIYSVIQAEINKHL, aa164-178, and ICS was performed. The frequency of IFN-γ+ (upper) or IL-2+ (lower) secreting CD3+/CD4+ pulmonary T cells was shown as percentage. (B) Anti-LcrV antibody titers for individual IgG isotypes in BAL. Immunization and injection routes were same as described in (A). Data are mean values from 3 independent experiments with similar results, using 3 mice per group. *p<0.05; **p<0.005; ***p<0.001